Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

Atsuhisa Sato, Koichi Hayashi, Takao Saruta

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

We have recently shown that mineralocorticoid receptor blockade may represent optimal therapy for patients with early diabetic nephropathy who show aldosterone breakthrough during angiotensin-converting enzyme (ACE) inhibitor treatment, and who no longer show the maximal antiproteinuric effects of ACE inhibition. In this study, we explored the effects of the mineralocorticoid receptor antagonist spironolactone on urinary protein excretion in patients with chronic renal disease with proteinuria persistently more than 0.5 g/d, despite maintained blood pressure (BP) control, and including the use of an ACE inhibitor (trandolapril) for at least 10 months. After a 12-week study period of spironolactone treatment (25 mg/d), BP did not change but urinary protein excretion was significantly reduced. The extent of the reduction was on average significantly greater in diabetic patients than in nondiabetics. In patients with diabetic nephropathy, although urinary type IV collagen did not decrease after conventional treatment, it was significantly reduced by spironolactone. None of the patients developed serious hyperkalemia, and no other adverse events were observed. All patients in this study had relatively well preserved renal function. In conclusion, the present study demonstrates that in patients with chronic renal disease with proteinuria persistently more than 0.5 g/d, despite BP control and the use of an ACE inhibitor, adding spironolactone to the conventional treatment produces beneficial effects on urinary protein excretion, particularly in patients with diabetes. Our study suggests that attenuation of mineralocorticoid receptor-mediated effects may become a new goal for patients who escape the antiproteinuric effects of the conventional treatment. Additional, larger, prospective, randomized double-blind studies will be needed for general acceptance of this strategy.

Original languageEnglish
Pages (from-to)44-49
Number of pages6
JournalAmerican Journal of Hypertension
Volume18
Issue number1
DOIs
Publication statusPublished - 2005 Jan

Fingerprint

Mineralocorticoid Receptors
Chronic Renal Insufficiency
Spironolactone
Angiotensin-Converting Enzyme Inhibitors
trandolapril
Diabetic Nephropathies
Blood Pressure
Proteinuria
Therapeutics
Mineralocorticoid Receptor Antagonists
Hyperkalemia
Proteins
Collagen Type IV
Peptidyl-Dipeptidase A
Aldosterone
Double-Blind Method
Kidney

Keywords

  • Aldosterone
  • angiotensin-converting enzyme inhibitor
  • chronic renal disease
  • diabetic nephropathy
  • mineralocorticoid receptor blockade

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. / Sato, Atsuhisa; Hayashi, Koichi; Saruta, Takao.

In: American Journal of Hypertension, Vol. 18, No. 1, 01.2005, p. 44-49.

Research output: Contribution to journalArticle

Sato, Atsuhisa ; Hayashi, Koichi ; Saruta, Takao. / Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. In: American Journal of Hypertension. 2005 ; Vol. 18, No. 1. pp. 44-49.
@article{66741da86d44427a894d654306569ea4,
title = "Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease",
abstract = "We have recently shown that mineralocorticoid receptor blockade may represent optimal therapy for patients with early diabetic nephropathy who show aldosterone breakthrough during angiotensin-converting enzyme (ACE) inhibitor treatment, and who no longer show the maximal antiproteinuric effects of ACE inhibition. In this study, we explored the effects of the mineralocorticoid receptor antagonist spironolactone on urinary protein excretion in patients with chronic renal disease with proteinuria persistently more than 0.5 g/d, despite maintained blood pressure (BP) control, and including the use of an ACE inhibitor (trandolapril) for at least 10 months. After a 12-week study period of spironolactone treatment (25 mg/d), BP did not change but urinary protein excretion was significantly reduced. The extent of the reduction was on average significantly greater in diabetic patients than in nondiabetics. In patients with diabetic nephropathy, although urinary type IV collagen did not decrease after conventional treatment, it was significantly reduced by spironolactone. None of the patients developed serious hyperkalemia, and no other adverse events were observed. All patients in this study had relatively well preserved renal function. In conclusion, the present study demonstrates that in patients with chronic renal disease with proteinuria persistently more than 0.5 g/d, despite BP control and the use of an ACE inhibitor, adding spironolactone to the conventional treatment produces beneficial effects on urinary protein excretion, particularly in patients with diabetes. Our study suggests that attenuation of mineralocorticoid receptor-mediated effects may become a new goal for patients who escape the antiproteinuric effects of the conventional treatment. Additional, larger, prospective, randomized double-blind studies will be needed for general acceptance of this strategy.",
keywords = "Aldosterone, angiotensin-converting enzyme inhibitor, chronic renal disease, diabetic nephropathy, mineralocorticoid receptor blockade",
author = "Atsuhisa Sato and Koichi Hayashi and Takao Saruta",
year = "2005",
month = "1",
doi = "10.1016/j.amjhyper.2004.06.029",
language = "English",
volume = "18",
pages = "44--49",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

AU - Sato, Atsuhisa

AU - Hayashi, Koichi

AU - Saruta, Takao

PY - 2005/1

Y1 - 2005/1

N2 - We have recently shown that mineralocorticoid receptor blockade may represent optimal therapy for patients with early diabetic nephropathy who show aldosterone breakthrough during angiotensin-converting enzyme (ACE) inhibitor treatment, and who no longer show the maximal antiproteinuric effects of ACE inhibition. In this study, we explored the effects of the mineralocorticoid receptor antagonist spironolactone on urinary protein excretion in patients with chronic renal disease with proteinuria persistently more than 0.5 g/d, despite maintained blood pressure (BP) control, and including the use of an ACE inhibitor (trandolapril) for at least 10 months. After a 12-week study period of spironolactone treatment (25 mg/d), BP did not change but urinary protein excretion was significantly reduced. The extent of the reduction was on average significantly greater in diabetic patients than in nondiabetics. In patients with diabetic nephropathy, although urinary type IV collagen did not decrease after conventional treatment, it was significantly reduced by spironolactone. None of the patients developed serious hyperkalemia, and no other adverse events were observed. All patients in this study had relatively well preserved renal function. In conclusion, the present study demonstrates that in patients with chronic renal disease with proteinuria persistently more than 0.5 g/d, despite BP control and the use of an ACE inhibitor, adding spironolactone to the conventional treatment produces beneficial effects on urinary protein excretion, particularly in patients with diabetes. Our study suggests that attenuation of mineralocorticoid receptor-mediated effects may become a new goal for patients who escape the antiproteinuric effects of the conventional treatment. Additional, larger, prospective, randomized double-blind studies will be needed for general acceptance of this strategy.

AB - We have recently shown that mineralocorticoid receptor blockade may represent optimal therapy for patients with early diabetic nephropathy who show aldosterone breakthrough during angiotensin-converting enzyme (ACE) inhibitor treatment, and who no longer show the maximal antiproteinuric effects of ACE inhibition. In this study, we explored the effects of the mineralocorticoid receptor antagonist spironolactone on urinary protein excretion in patients with chronic renal disease with proteinuria persistently more than 0.5 g/d, despite maintained blood pressure (BP) control, and including the use of an ACE inhibitor (trandolapril) for at least 10 months. After a 12-week study period of spironolactone treatment (25 mg/d), BP did not change but urinary protein excretion was significantly reduced. The extent of the reduction was on average significantly greater in diabetic patients than in nondiabetics. In patients with diabetic nephropathy, although urinary type IV collagen did not decrease after conventional treatment, it was significantly reduced by spironolactone. None of the patients developed serious hyperkalemia, and no other adverse events were observed. All patients in this study had relatively well preserved renal function. In conclusion, the present study demonstrates that in patients with chronic renal disease with proteinuria persistently more than 0.5 g/d, despite BP control and the use of an ACE inhibitor, adding spironolactone to the conventional treatment produces beneficial effects on urinary protein excretion, particularly in patients with diabetes. Our study suggests that attenuation of mineralocorticoid receptor-mediated effects may become a new goal for patients who escape the antiproteinuric effects of the conventional treatment. Additional, larger, prospective, randomized double-blind studies will be needed for general acceptance of this strategy.

KW - Aldosterone

KW - angiotensin-converting enzyme inhibitor

KW - chronic renal disease

KW - diabetic nephropathy

KW - mineralocorticoid receptor blockade

UR - http://www.scopus.com/inward/record.url?scp=13244298395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244298395&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2004.06.029

DO - 10.1016/j.amjhyper.2004.06.029

M3 - Article

C2 - 15691616

AN - SCOPUS:13244298395

VL - 18

SP - 44

EP - 49

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 1

ER -